Norges Bank’s Xeris Biopharma Holdings XERS Stock Holding History

Norges Bank’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-800,700	Closed	-$6.29M	–	1436
2025 Q4	$6.29M	Buy	+800,700	New	+$6.3M	﹤0.01%	1353
2025 Q3	–	Sell	-561,700	Closed	-$2.62M	–	1601
2025 Q2	$2.62M	Sell	561,700 -262,100	-32%	-$1.2M	﹤0.01%	1395
2025 Q1	$4.52M	Buy	+823,800	New	+$3.33M	﹤0.01%	1379
2018 Q3	–	Sell	-15,000	Closed	-$285K	–	2169
2018 Q2	$285K	Buy	+15,000	New	+$291K	﹤0.01%	2104

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank's XERS Position: Q1 2026 in Review

Norges Bank sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 800,700 shares — an estimated $6.29M sold.

Norges Bank first reported a position in XERS in Q2 2018 and held it in 4 quarters. The position peaked at $6.29M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Norges Bank reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 800,700 Xeris Biopharma Holdings shares in Q1 2026, an estimated $6.29M.
Norges Bank first reported a position in Xeris Biopharma Holdings in Q2 2018 and held it in 4 quarters.
Norges Bank's Xeris Biopharma Holdings position peaked at $6.29M in Q4 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.